New combo drug trial hopes to tame tough breast cancer

NCT ID NCT04288089

Ongoing Disease control Sponsor: Eisai Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug (H3B-6545) combined with an existing drug (palbociclib) in women with advanced or metastatic ER+ HER2- breast cancer. The main goal is to find the safest dose and understand side effects. About 31 women who have already tried other treatments will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC ESTROGEN RECEPTOR-POSITIVE HER2-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASMS GENES, ERBB-2 RECEPTORS, ESTROGEN

Contacts and locations

Locations

Comprehensive Cancer Centers of Nevada

Las Vegas, Nevada, 89169, United States
Florida Cancer Specialists South - SCRI - PPDS

Sarasota, Florida, 34232, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Royal Marsden NHS Foundation Trust

London, United Kingdom
Royal Marsden NHS Foundation Trust

Sutton, United Kingdom
Saint Luke's Cancer Institute

Kansas City, Missouri, 64111, United States
Sarah Cannon Research Institute UK - SCRI

London, United Kingdom
Tennessee Oncology, PLLC - SCRI - PPDS

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.